Drug intelligence / Profile preview

PF-07899895

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07899895 is an investigational oral small molecule drug developed by Pfizer for the treatment of ulcerative colitis. It acts as an inhibitor of salt-inducible kinases (SIK), specifically targeting SIK1, and functions as a protein-serine-threonine kinase inhibitor. The drug is currently in Phase 1 clinical trials, with studies focused on evaluating its safety, tolerability, and pharmacokinetics in healthy adults. As a new molecular entity, PF-07899895 represents a novel approach to modulating inflammatory pathways implicated in ulcerative colitis.

Targets

SIK1 (Salt-inducible kinase 1)

Beyond the preview

Go deeper on PF-07899895.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07899895.

Explore the full profile